Spoken Alpha
NRX Pharmaceuticals, Inc.
NRx Pharmaceuticals develops novel therapeutics for central nervous system disorders including suicidal depression, PTSD, chronic pain, and schizophrenia. The company's lead candidates—NRX-100 and KETAFREE (preservative-free ketamine formulations) and NRX-101 (an oral combination of D-cycloserine and lurasidone)—are in FDA review for approval.
NRX Pharmaceuticals, Inc has a $714.6M market cap.
Most recent reported earnings: Q2 FY2021 (Sep 29, 2021).
20 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-05-21.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Spoken Alpha tracks NRXPW's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 5/10 quarters with 70% positive reaction rate
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for NRXPW.
$ curl https://api.spokenalpha.com/v1/companies/NRXPWFAQ
Spoken Alpha indexes NRXPW's earnings call transcripts at https://spokenalpha.com/companies/NRXPW. Each call links to attributed speakers and parsed analyst Q&A. NRX Pharmaceuticals, Inc.'s own investor relations page is at https://ir.nrxpharma.com/.
NRX Pharmaceuticals, Inc. (NRXPW) held its most recent earnings call on 2026-05-18, covering fiscal Q1 2026.
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2021 | 2021-09-29 | $-0.40 | $0.00 | — | $0 | — | — | EODHD |
| Q1 FY2021 | 2021-06-29 | $-6.51 | $0.00 | — | $-113.1K | — | — | EODHD |
| Q4 FY2020 | 2021-03-30 | $-2.26 | $0.00 | — | — | — | — | EODHD |
| Q2 FY2020 | 2020-09-29 | $-0.15 | $0.00 | — | $25.0K | — | — | EODHD |
| Q1 FY2020 | 2020-06-29 | $0.00 | $0.00 | — | $113.1K | — | — | EODHD |
| Q4 FY2019 | 2020-03-30 | $-0.15 | $0.00 | — | $172.3K | — | — | EODHD |
Source: EODHD. NRXPW reported actuals as published; sparse fields render as —.
Consistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Missed in 2 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $2.34 | $2.44 | -4.3% | -2.4% | -3.9% |
| Q4 FY2026 | $2.78 | $2.67 | +4.2% | +2.6% | +1.6% |
| Q3 FY2026 | $2.81 | $2.58 | +9.0% | +3.8% | +4.0% |
| Q2 FY2026 | $2.69 | $2.74 | -2.0% | -4.0% | -6.7% |
| Q1 FY2025 | $2.66 | $2.71 | -1.8% | +2.3% | +2.5% |
CEO since 2022 • 7/16 beats (44%) • last call held guidance Q2 FY2026
| Q4 FY2025 |
| $2.53 |
| $2.64 |
| -4.2% |
| +0.4% |
| -2.1% |
| Q3 FY2025 | $2.61 | $2.59 | +0.6% | +1.3% | -0.6% |
| Q2 FY2025 | $2.90 | $2.74 | +5.8% | -2.5% | +0.5% |
| Q1 FY2024 | $3.08 | $2.88 | +7.0% | +1.6% | +0.3% |
| Q4 FY2024 | $2.66 | $2.72 | -2.2% | +0.9% | +0.3% |